Core Viewpoint - Affimed N.V. has filed for insolvency proceedings due to insufficient funds to continue operations and has determined that it is overindebted [1][2][3][4]. Group 1: Company Situation - Affimed N.V. is a clinical-stage immuno-oncology company focused on harnessing the innate immune system to combat cancer [5]. - The company has been unable to raise sufficient capital despite ongoing fundraising efforts, leading to substantial doubt about its ability to continue as a going concern [2][3]. - The management board has concluded that both Affimed N.V. and its subsidiary Affimed GmbH are overindebted and must file for insolvency under German law [3][4]. Group 2: Insolvency Proceedings - On May 13, 2025, the management board filed for ordinary insolvency proceedings for both Affimed N.V. and Affimed GmbH with the local court in Mannheim, Germany [4]. - The outcome of the insolvency proceedings remains uncertain, including whether the companies will emerge as going concerns [4]. - The filing for insolvency will lead to the suspension and subsequent delisting of the company's common shares from The Nasdaq Global Market [4].

Core Insights - Affimed N.V. announced that an abstract on the phase 2 LuminICE-203 study of its innate cell engager (ICE) acimtamig in combination with AlloNK (AB-101) has been accepted for oral presentation at the ASCO Annual Meeting scheduled for May 30 – June 3, 2025 [1] - Two abstracts on AFM24 in combination with atezolizumab for non-small cell lung cancer (NSCLC) have also been accepted for poster presentations at the same event [1] Presentation Details - The oral presentation will cover the completed dose-finding part of the phase 2 study of acimtamig in combination with AlloNK for relapsed or refractory classical Hodgkin lymphoma, scheduled for May 30, 2025 [2] - The poster presentations will include initial results from a phase 2a study of AFM24 in combination with atezolizumab for advanced/metastatic EGFR-expressing NSCLC without driver mutations and for NSCLC with EGFR kinase domain mutations, both scheduled for June 2, 2025 [2] Company Overview - Affimed N.V. is a clinical-stage immuno-oncology company focused on harnessing the innate immune system to combat cancer through its proprietary innate cell engagers (ICE) [4] - The company is headquartered in Mannheim, Germany, and aims to provide innovative therapies that enable tumor-targeted approaches to treat various hematologic and solid tumors [4]

Core Points - Affimed N.V. has received a notice from Nasdaq indicating that its common shares have closed below the minimum bid price of $1.00 for the last 30 consecutive business days [1] - The company has until October 13, 2025, to regain compliance with the Minimum Bid Price Rule, with the possibility of transferring to the Nasdaq Capital Market for an additional 180 days if necessary [2] - The notice does not have an immediate effect on the listing or trading of the company's shares, and the company plans to monitor its bid price and explore options for compliance [3] Company Overview - Affimed N.V. is a clinical-stage immuno-oncology company focused on harnessing the innate immune system to combat cancer through its proprietary innate cell engagers (ICE) [4] - The company is headquartered in Mannheim, Germany, and is led by a team of experienced biotechnology and pharmaceutical professionals [4]